About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Gt(ROSA)26Sortm1(cre/ERT2)Thl
targeted mutation 1, Thomas Ludwig
MGI:3701992
Summary 15 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sortm1(Tcfe2a/Tal1)Xhsu involves: 129/Sv * C57BL/6 MGI:3833565
cn2
 		Rr96tm1.1Tich/Rr96+
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sortm1(rtTA*M2)Jae 		involves: 129 * 129S4/SvJae * C57BL/6 MGI:5470231
cn3
 		Atmtm1Shzh/Atmtm2.1Fwa
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+ 		involves: 129 * 129S6/SvEvTac MGI:5463807
cn4
 		Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Pknox1tm1.1Rygo/Pknox1tm1.1Rygo 		involves: 129 * C57BL/6 * C57BL/6JJcl MGI:6887744
cn5
 		Flt1tm1.1Fong/Flt1tm1.1Fong
Kdrtm1Jrt/Kdr+
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+ 		involves: 129 * C57BL/6NCr * CD-1 MGI:5523778
cn6
 		Nt5c2tm1.1Aafo/Nt5c2+
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+ 		involves: 129 * C57BL/6 * SJL MGI:6147350
cn7
 		Gt(ROSA)26Sortm1(cre/ERT2)Thl/0
Picalmtm1.1Tmae/Picalmtm1.1Tmae 		involves: 129 * C57BL/6 * SJL MGI:5639333
cn8
 		Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Kat8tm1Thl/Kat8tm1Thl 		involves: 129S1/Sv MGI:3769382
cn9
 		Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Kat8tm1Thl/Kat8+ 		involves: 129S1/Sv MGI:3769383
cn10
 		Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Id1tm3Bene/Id1tm3Bene
Id2tm1Xdz/Id2tm1Xdz
Id3tm1Zhu/Id3tm1Zhu 		involves: 129S4/SvJaeSor * C57BL/6 MGI:5428955
cn11
 		Flt1tm1.1Fong/Flt1tm1.1Fong
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+ 		involves: 129S6/SvEvTac * C57BL/6NCr * CD-1 MGI:5523779
cn12
 		Card11tm1.1Litt/Card11tm1.1Litt
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Tg(TcraTcrb)425Cbn/? 		involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6 MGI:5307048
cn13
 		Errfi1tm1Jwj/Errfi1tm1Jwj
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+ 		involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL MGI:4943702
cn14
 		Zfxtm1.1Reiz/Y
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+ 		involves: 129/Sv * 129S6/SvEvTac MGI:3848801
cn15
 		Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Mcl1tm1Ywh/Mcl1tm1Ywh 		involves: 129/Sv * 129S6/SvEvTac * C57BL/6 MGI:3801467


Genotype
MGI:3833565
cn1
Allelic
Composition		 Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sortm1(Tcfe2a/Tal1)Xhsu
Genetic
Background		 involves: 129/Sv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
Gt(ROSA)26Sortm1(Tcfe2a/Tal1)Xhsu mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
abnormal lymphopoiesis ( J:144569 )
• lin - kit+ Sca-1+ progenitor cells isolated from the bone marrow of mice treated with tamoxifen produce 20- to 40- fold more B cells than controls when cultured under condition supporting lymphopoiesis
abnormal myelopoiesis ( J:144569 )
• lin- kit+ Sca-1+ progenitor cells isolated from the bone marrow of mice treated with tamoxifen produce 10-fold lower percentages and numbers of myeloid lineage cells in vitro than controls
• however, normal number of myeloid cells are produced from myeloid progenitor cells

immune system
abnormal lymphopoiesis ( J:144569 )
• lin - kit+ Sca-1+ progenitor cells isolated from the bone marrow of mice treated with tamoxifen produce 20- to 40- fold more B cells than controls when cultured under condition supporting lymphopoiesis
abnormal myelopoiesis ( J:144569 )
• lin- kit+ Sca-1+ progenitor cells isolated from the bone marrow of mice treated with tamoxifen produce 10-fold lower percentages and numbers of myeloid lineage cells in vitro than controls
• however, normal number of myeloid cells are produced from myeloid progenitor cells




Genotype
MGI:5470231
cn2
Allelic
Composition		 Rr96tm1.1Tich/Rr96+
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background		 involves: 129 * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (30 available); any Gt(ROSA)26Sor mutation (991 available)
Rr96tm1.1Tich mutation (0 available); any Rr96 mutation (0 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
abnormal T cell differentiation ( J:191711 )
• derepression of Cd4 occurs in all CD4- T cells
• T cell expression of CD4 increases rapidly after cre activation

hematopoietic system
abnormal T cell differentiation ( J:191711 )
• derepression of Cd4 occurs in all CD4- T cells
• T cell expression of CD4 increases rapidly after cre activation




Genotype
MGI:5463807
cn3
Allelic
Composition		 Atmtm1Shzh/Atmtm2.1Fwa
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Genetic
Background		 involves: 129 * 129S6/SvEvTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Atmtm1Shzh mutation (0 available); any Atm mutation (170 available)
Atmtm2.1Fwa mutation (2 available); any Atm mutation (170 available)
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cellular
chromosomal instability ( J:191288 )
• B cells from tamoxifen-treated mice exhibit reduced class switch recombination with increased genomic instability (especially chromatid breaks) compared with wild-type cells but at the same level as in Atmtm1Fwa cells

immune system
abnormal class switch recombination ( J:191288 )
• B cells from tamoxifen-treated mice exhibit reduced class switch recombination with increased genomic instability (especially chromatid breaks) compared with wild-type cells but at the same level as in Atmtm1Fwa cells

hematopoietic system
abnormal class switch recombination ( J:191288 )
• B cells from tamoxifen-treated mice exhibit reduced class switch recombination with increased genomic instability (especially chromatid breaks) compared with wild-type cells but at the same level as in Atmtm1Fwa cells




Genotype
MGI:6887744
cn4
Allelic
Composition		 Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Pknox1tm1.1Rygo/Pknox1tm1.1Rygo
Genetic
Background		 involves: 129 * C57BL/6 * C57BL/6JJcl
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
Pknox1tm1.1Rygo mutation (1 available); any Pknox1 mutation (90 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
reproductive system
reproductive system phenotype ( J:258387 )
N
• three weeks after tamoxifen treatment, adult testis size and weight is markedly but not significantly decreased relative to similarly treated controls
abnormal spermatogonia morphology ( J:258387 )
• after tamoxifen treatment, GFRalpha1+ cells (corresponding to Asingle~paired spermatogonia in control testis) form Aaligned-like morphologies in adult testes
• c-Kit+ cells aligned more than 32 appear to be absent whereas Aaligned and A1-type spermatogonia are present in control testes, suggesting that c-Kit+ Aaligned spermatogonia fail to differentiate into A1 spermatogonia
decreased male germ cell number ( J:258387 )
• after tamoxifen treatment, most seminiferous tubules lack SCP3+ meiotic cells
azoospermia ( J:258387 )
• epididymides of tamoxifen-treated adult males are devoid of sperm
increased testis apoptosis ( J:258387 )
• after tamoxifen treatment, adult testes show a marked increase in TUNEL+ apoptotic cells relative to similarly treated controls
seminiferous tubule degeneration ( J:258387 )
• after tamoxifen treatment, adult seminiferous tubules appear atrophied and contain very few spermatocytes; however, germ cells beneath the basement membrane (likely spermatogonia and haploid cells) appear to exist
• most seminiferous tubules lack SCP3+ meiotic cells
arrest of spermatogenesis ( J:258387 )
• after tamoxifen treatment, adult spermatogenesis is arrested at the c-Kit+ spermatogonia stage

cellular
abnormal spermatogonia morphology ( J:258387 )
• after tamoxifen treatment, GFRalpha1+ cells (corresponding to Asingle~paired spermatogonia in control testis) form Aaligned-like morphologies in adult testes
• c-Kit+ cells aligned more than 32 appear to be absent whereas Aaligned and A1-type spermatogonia are present in control testes, suggesting that c-Kit+ Aaligned spermatogonia fail to differentiate into A1 spermatogonia
decreased male germ cell number ( J:258387 )
• after tamoxifen treatment, most seminiferous tubules lack SCP3+ meiotic cells
azoospermia ( J:258387 )
• epididymides of tamoxifen-treated adult males are devoid of sperm
increased testis apoptosis ( J:258387 )
• after tamoxifen treatment, adult testes show a marked increase in TUNEL+ apoptotic cells relative to similarly treated controls

endocrine/exocrine glands
increased testis apoptosis ( J:258387 )
• after tamoxifen treatment, adult testes show a marked increase in TUNEL+ apoptotic cells relative to similarly treated controls
seminiferous tubule degeneration ( J:258387 )
• after tamoxifen treatment, adult seminiferous tubules appear atrophied and contain very few spermatocytes; however, germ cells beneath the basement membrane (likely spermatogonia and haploid cells) appear to exist
• most seminiferous tubules lack SCP3+ meiotic cells




Genotype
MGI:5523778
cn5
Allelic
Composition		 Flt1tm1.1Fong/Flt1tm1.1Fong
Kdrtm1Jrt/Kdr+
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Genetic
Background		 involves: 129 * C57BL/6NCr * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Flt1tm1.1Fong mutation (1 available); any Flt1 mutation (76 available)
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
Kdrtm1Jrt mutation (1 available); any Kdr mutation (74 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cardiovascular system
increased angiogenesis ( J:202202 )
• in the brain and liver of tamoxifen treated mice compared with control mice but not as severe as in mice also lacking the Kdr null allele
• some small focal areas in the retina in tamoxifen-treated mice relative to mice lacking the Kdr null allele
• however, angiogenesis in the heart is normal




Genotype
MGI:6147350
cn6
Allelic
Composition		 Nt5c2tm1.1Aafo/Nt5c2+
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Genetic
Background		 involves: 129 * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
Nt5c2tm1.1Aafo mutation (0 available); any Nt5c2 mutation (36 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
abnormal bone marrow cell physiology ( J:257751 )
• bone marrow cells used in a transplantation experiment following tamoxifen-induction produce NOTCH1-induced tumors that are resistant to 6-mercaptopurine chemotherapy unlike control cells




Genotype
MGI:5639333
cn7
Allelic
Composition		 Gt(ROSA)26Sortm1(cre/ERT2)Thl/0
Picalmtm1.1Tmae/Picalmtm1.1Tmae
Genetic
Background		 involves: 129 * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
Picalmtm1.1Tmae mutation (1 available); any Picalm mutation (42 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
abnormal erythropoiesis ( J:220728 )
• inefficient erythroid differentiation in the spleen following tamoxifen treatment
hypochromic microcytic anemia ( J:220728 )
• mice develop microcytic and hypochromic anemia following tamoxifen treatment

integument
diluted coat color ( J:220728 )
• gray coat color

pigmentation
diluted coat color ( J:220728 )
• gray coat color




Genotype
MGI:3769382
cn8
Allelic
Composition		 Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Kat8tm1Thl/Kat8tm1Thl
Genetic
Background		 involves: 129S1/Sv
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
Kat8tm1Thl mutation (0 available); any Kat8 mutation (38 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cellular
decreased fibroblast proliferation ( J:128936 )
• following treatment with tamoxifen, mouse embryonic fibroblasts exhibit a decrease in proliferation compared to wild-type




Genotype
MGI:3769383
cn9
Allelic
Composition		 Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Kat8tm1Thl/Kat8+
Genetic
Background		 involves: 129S1/Sv
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
Kat8tm1Thl mutation (0 available); any Kat8 mutation (38 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cellular
increased cellular sensitivity to ionizing radiation ( J:128936 )
• following treatment with tamoxifen, cell survival of mouse embryonic fibroblasts following treatment with ionizing radiation is slightly decreased compared to in wild-type cells
decreased fibroblast proliferation ( J:128936 )
• following treatment with tamoxifen, mouse embryonic fibroblasts exhibit a modest decrease in proliferation compared to wild-type
abnormal DNA repair ( J:128936 )
• following treatment with tamoxifen, the number of chromosome abnormalities in mouse embryonic fibroblasts is increased compared to in wild-type cells

homeostasis/metabolism
abnormal DNA repair ( J:128936 )
• following treatment with tamoxifen, the number of chromosome abnormalities in mouse embryonic fibroblasts is increased compared to in wild-type cells




Genotype
MGI:5428955
cn10
Allelic
Composition		 Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Id1tm3Bene/Id1tm3Bene
Id2tm1Xdz/Id2tm1Xdz
Id3tm1Zhu/Id3tm1Zhu
Genetic
Background		 involves: 129S4/SvJaeSor * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
Id1tm3Bene mutation (0 available); any Id1 mutation (10 available)
Id2tm1Xdz mutation (0 available); any Id2 mutation (21 available)
Id3tm1Zhu mutation (1 available); any Id3 mutation (16 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cellular
premature neuronal precursor differentiation ( J:185426 )
• following tamoxifen-treatment of cultured neural stem cells

nervous system
premature neuronal precursor differentiation ( J:185426 )
• following tamoxifen-treatment of cultured neural stem cells




Genotype
MGI:5523779
cn11
Allelic
Composition		 Flt1tm1.1Fong/Flt1tm1.1Fong
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Genetic
Background		 involves: 129S6/SvEvTac * C57BL/6NCr * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Flt1tm1.1Fong mutation (1 available); any Flt1 mutation (76 available)
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cardiovascular system
increased angiogenesis ( J:202202 )
• with increased surface area and branching points in the retinal inner plexiform layer of mice treated with tamoxifen from P1 to P4
• in the retinal tissue between the inner plexiform layer and ganglion cell layer of mice treated with tamoxifen from P1 to P4
• in the retinal inner and outer plexiform layer, lung, heart, brain, kidney, liver and cornea of mice treated with tamoxifen as adults
• after left anterior descending coronary artery ligation in tamoxifen-treated mice
• the retina of neonates treated with tamoxifen exhibit increased tip cells by P5 compared with control mice
• however, tamoxifen-treated mice exhibit normal vascular maturation and perfusion
decreased myocardial infarct size ( J:202202 )
• 8 weeks after left anterior descending coronary artery ligation, tamoxifen-treated mice exhibit decreased infarct area and increase in PECAM-1 positive vessels in infarcted and non-infarcted areas compared with control mice
increased vascular permeability ( J:202202 )
• in tamoxifen treated mice exposed to high concentration of VEGF-A
• however, permeability is normal without VEGF-A treatment or with the addition of SU1498 (anti-VEGF-A inhibitor)

cellular
increased endothelial cell proliferation ( J:202202 )
• in the retina (ganglion cell layer and inner and outer plexiform layer) of tamoxifen-treated mice at P21

growth/size/body
decreased body size ( J:202202 )
• at P21 in mice treated with tamoxifen as neonates
• however, mice treated with tamoxifen as adults are not visibly different from wild-type mice

hematopoietic system
increased macrophage cell number ( J:202202 )
• at P21 in the liver of tamoxifen-treated mice
• however, tamoxifen-treated mice subjected to left anterior descending coronary artery ligation exhibit normal macrophage numbers in the infarcted myocardium

homeostasis/metabolism
decreased myocardial infarct size ( J:202202 )
• 8 weeks after left anterior descending coronary artery ligation, tamoxifen-treated mice exhibit decreased infarct area and increase in PECAM-1 positive vessels in infarcted and non-infarcted areas compared with control mice

immune system
increased macrophage cell number ( J:202202 )
• at P21 in the liver of tamoxifen-treated mice
• however, tamoxifen-treated mice subjected to left anterior descending coronary artery ligation exhibit normal macrophage numbers in the infarcted myocardium




Genotype
MGI:5307048
cn12
Allelic
Composition		 Card11tm1.1Litt/Card11tm1.1Litt
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Tg(TcraTcrb)425Cbn/?
Genetic
Background		 involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Card11tm1.1Litt mutation (0 available); any Card11 mutation (59 available)
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
Tg(TcraTcrb)425Cbn mutation (3 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
abnormal T cell activation ( J:180410 )
• reactivation is prevented after in vitro activation with Ova and tamoxifen treatment

hematopoietic system
abnormal T cell activation ( J:180410 )
• reactivation is prevented after in vitro activation with Ova and tamoxifen treatment




Genotype
MGI:4943702
cn13
Allelic
Composition		 Errfi1tm1Jwj/Errfi1tm1Jwj
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Genetic
Background		 involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Errfi1tm1Jwj mutation (0 available); any Errfi1 mutation (18 available)
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
respiratory system
respiratory system phenotype ( J:153715 )
N
• following tamoxifen treatment, mice display normal alveolar spaces and normal lung structure with no detectable mucosal cells
• expression of key lung molecular markers remains normal in adult lungs

reproductive system
uterus hyperplasia ( J:153715 )
• following tamoxifen treatment, mice display uterine hyperplasia

integument
increased skin papilloma incidence ( J:153715 )
• following tamoxifen treatment, mice display dermal papillomas

neoplasm
increased skin papilloma incidence ( J:153715 )
• following tamoxifen treatment, mice display dermal papillomas




Genotype
MGI:3848801
cn14
Allelic
Composition		 Zfxtm1.1Reiz/Y
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Genetic
Background		 involves: 129/Sv * 129S6/SvEvTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
Zfxtm1.1Reiz mutation (0 available); any Zfx mutation (33 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
abnormal common lymphocyte progenitor cell morphology ( J:149654 )
• as early as 4 days after tamoxifen-induction
decreased hematopoietic stem cell number ( J:149654 )
• following tamoxifen treatment, the number of hematopoietic stem cell-containing LSK populations is decreased compared to in similarly treated wild-type mice
abnormal hematopoietic system physiology ( J:149654 )
• following tamoxifen treatment, maintenance of adult hematopoietic cells is abolished compared to in similarly treated wild-type mice




Genotype
MGI:3801467
cn15
Allelic
Composition		 Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Mcl1tm1Ywh/Mcl1tm1Ywh
Genetic
Background		 involves: 129/Sv * 129S6/SvEvTac * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT2)Thl mutation (0 available); any Gt(ROSA)26Sor mutation (991 available)
Mcl1tm1Ywh mutation (0 available); any Mcl1 mutation (35 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
increased T cell apoptosis ( J:137400 )
• in culture following treatment with tamoxifen regardless of activation status T cell survival is decreased comapred to similarly treated wild-type cells

cellular
increased T cell apoptosis ( J:137400 )
• in culture following treatment with tamoxifen regardless of activation status T cell survival is decreased comapred to similarly treated wild-type cells

hematopoietic system
increased T cell apoptosis ( J:137400 )
• in culture following treatment with tamoxifen regardless of activation status T cell survival is decreased comapred to similarly treated wild-type cells




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
10/09/2024
MGI 6.24 		The Jackson Laboratory